GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) is a publicly traded Healthcare sector company. As of May 20, 2026, GSK trades at $50.83 with a market cap of $100.90B and a P/E ratio of 0.00. GSK moved -0.54% today. Year to date, GSK is +3.59%; over the trailing twelve months it is +32.24%. Its 52-week range spans $31.72 to $61.70. Analyst consensus is neutral with an average price target of $54.00. Rallies surfaces GSK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
GT Biopharma Doses First GTB-5550 Patient, Intensifying B7-H3 Race with GSK: GT Biopharma dosed first patient on May 14 in its Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer cell engager, with $9M cash runway through Q4 2026 and updates expected in 2H 2026. GSK’s B7-H3 ADC faces competition from this subcutaneously dosed TriKE in the $362B solid tumor market.
| Metric | Value |
|---|---|
| Price | $50.83 |
| Market Cap | $100.90B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.46% |
| 52-Week High | $61.70 |
| 52-Week Low | $31.72 |
| Volume | 2.56M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
1 analysts cover GSK: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $54.00.